IOVA - Iovance Biotherapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
0
0
0
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
0
Operating Expenses
Research Development
139,203
99,828
71,615
28,037
15,470
Selling General and Administrative
37,502
28,430
21,262
25,602
12,390
Total Operating Expenses
176,705
128,258
92,877
53,639
27,860
Operating Income or Loss
-176,705
-128,258
-92,877
-53,639
-27,860
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
-
-
-
0
0
Income Before Tax
-166,563
-123,580
-92,064
-52,894
-27,660
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-166,563
-123,580
-92,064
-52,894
-27,660
Net Income
-166,563
-123,580
-92,064
-52,894
-27,660
Net Income available to common shareholders
-166,563
-123,580
-92,064
-102,348
-27,660
Reported EPS
Basic
-
-1.27
-1.41
-1.85
-0.62
Diluted
-
-1.27
-1.41
-1.85
-0.62
Weighted average shares outstanding
Basic
-
97,277
65,242
55,268
44,410
Diluted
-
97,277
65,242
55,268
44,410
EBITDA
-
-128,258
-92,877
-53,639
-27,860